Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$95 Mln
Revenue (TTM)
$28 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.3
Industry P/E
--
EV/EBITDA
-7.2
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
979,950,016
CFO
$-96.69 Mln
EBITDA
$-125.74 Mln
Net Profit
$-137.49 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Zomedica (ZOM)
| -54.2 | 4.0 | -55.1 | -62.1 | -39.1 | -21.7 | -- |
|
BSE Sensex*
| 3.7 | -1.6 | 9.6 | 5.9 | 14.3 | 19.1 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Zomedica (ZOM)
| 22.7 | -46.9 | 32.9 | -30.2 | -73.1 | -37.6 | 91.7 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Zomedica (ZOM)
|
0.1 | 95.4 | 27.5 | -101.6 | -167.9 | -60.6 | -- | 0.3 |
| 3.2 | 955.2 | 23.1 | -167.9 | -1,294.8 | -16 | -- | 0.9 | |
| 8.2 | 1,093.0 | 247.3 | 39.9 | 7.2 | 10.8 | 30 | 3.1 | |
| 3.7 | 156.5 | 0.0 | -27.0 | -- | -65.9 | -- | 4.6 | |
| 1.9 | 13.5 | 0.0 | -5.8 | -- | -66.6 | -- | 2.1 | |
| 1.7 | 74.1 | 0.0 | -28.5 | -- | -23.7 | -- | 0.7 | |
| 7.9 | 219.0 | 30.9 | -14.1 | -32.8 | -- | -- | 57.9 | |
| 2.5 | 3.3 | 2,375.8 | -6,375.8 | -177.6 | -181.4 | -- | 0.4 | |
| 1.7 | 89.8 | 0.0 | -51.9 | -- | -- | -- | 5.0 | |
| 32.8 | 2,513.8 | 7.5 | -251.5 | -2,936.8 | -33.5 | -- | 3.6 |
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic... platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan. Read more
President, CEO & Director
Mr. Larry C. Heaton II
President, CEO & Director
Mr. Larry C. Heaton II
Headquarters
Ann Arbor, MI
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Zomedica Corp (ZOM) stood at $ 216 Mln as on 31-Mar-25
The share price of Zomedica Corp (ZOM) is $0.06 (NYSE) as of 06-May-2025 09:30 EDT. Zomedica Corp (ZOM) has given a return of -39.06% in the last 3 years.
Zomedica Corp (ZOM) has a market capitalisation of $ 95 Mln as on 06-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Zomedica Corp (ZOM) is 0.26 times as on 06-May-2025, a 92% discount to its peers’ median range of 3.43 times.
Since, TTM earnings of Zomedica Corp (ZOM) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Zomedica Corp (ZOM) and enter the required number of quantities and click on buy to purchase the shares of Zomedica Corp (ZOM).
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.
The CEO & director of Mr. Larry C. Heaton II. is Zomedica Corp (ZOM), and CFO & Sr. VP is Mr. Larry C. Heaton II.
There is no promoter pledging in Zomedica Corp (ZOM).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
328
|
|
|
145
|
|
|
86
|
|
|
23
|
|
|
17
|
|
|
10
|
|
|
7
|
|
|
1
|
|
|
0
|
| Zomedica Corp. (ZOM) | Ratios |
|---|---|
|
Return on equity(%)
|
-60.62
|
|
Operating margin(%)
|
-167.86
|
|
Net Margin(%)
|
-369.26
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Zomedica Corp (ZOM) was $0 Mln.
